ClinicalTrials.gg
CompletedNCT07844122Updated Sep 28, 2026

Effects of Caffeine on Agility in Amateur Soccer Players

An interventional study of Caffeine 300 MG and Placebo in Healthy Adult Male, sponsored by Comenius University. Completed at 1 site in Slovakia. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Comenius University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Oct 2024, registered Sep 2026).
Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing caffeine in Motor Activity — 2 open to participants now, 2 under way, none of them phase 3. Caffeine · Motor Activity.

Enrollment
10th of 13
16 · median 23
Started
2024
with 1 other
No phase
11 of 13
2 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Comenius University

Among the 13 studies testing caffeine in Motor Activity, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 11 with no phase, and was the 13th registered.

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

2 of the 13 studies testing caffeine in Motor Activity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About caffeine

Caffeine: first FDA approval 1948 (CAFERGOT), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 18 Years to 35 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing caffeine in Motor Activity, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled crossover clinical trial aims to investigate the acute effects of caffeine supplementation on motor and perceptual-cognitive components of agility performance in male amateur soccer players.

The main questions are: i) Does acute caffeine supplementation improve motor performance, including countermovement jump height, drop-jump reactive strength, and planned agility? ii) Does acute caffeine supplementation improve perceptual-cognitive performance during reactive agility tasks involving light and human stimuli?

Participants will complete two experimental conditions in randomized order, receiving either 300 mg of caffeine (\~3.7 miligrams/kilograms of body mass) or placebo pills. Following ingestion, participants will perform countermovement and drop jumps and three Y-shaped agility tests assessing planned agility, reactive agility to a light stimulus, and reactive agility to a human stimulus.

Read the detailed description

Caffeine supplementation was investigated for its potential to differentially affect motor and perceptual-cognitive aspects of performance in athletes. Participants were recruited from amateur soccer clubs competing in the third to fifth tiers of the Slovak league system and fifth to sixth tiers of the Austrian league system. A pre-selection questionnaire was used to assess relevant demographic, sporting, health, injury, and habitual caffeine consumption characteristics. Players with habitual caffeine intake above 400 miligrams/day were excluded. A familiarization session was conducted approximately one week before the experimental measurements to practice the procedures and reduce learning effects.

The intervention consisted of a single 300 milligrams caffeine dose, corresponding to approximately 3.7 miligrams/kilograms of body mass. The placebo consisted of potato starch. Caffeine and placebo capsules were visually identical. Condition order was determined by simple randomization using an independent online randomization generator, and the investigator responsible for randomization was not involved in testing. Participants and testers remained unaware of the assigned condition.

Participants were instructed to maintain their usual training regimen, abstain from caffeine-containing products for at least 24 hours before testing, and avoid intense physical activity on the preceding day. The two experimental sessions were conducted seven days apart, during the same period of the soccer season and at the same time of day to reduce potential effects of recovery and circadian variation. Diet, fluid intake, and sleep were not standardized.

After capsule ingestion, participants completed a standardized dynamic warm-up involving aerobic activation, lunges, dynamic stretching, and countermovement jumps. Testing subsequently assessed explosive lower-limb performance and agility under controlled laboratory and field conditions. The agility assessment used a Y-shaped setup and distinguished between a predetermined change-of-direction task and reactive tasks requiring a response to either a visual light stimulus or a live human stimulus.

The human-stimulus condition was designed to introduce a greater perceptual and decision-making component than the planned condition. Participants were required to perceive the tester's movement and rapidly select the appropriate alternative direction. Reactive trials were repeated when predefined technical errors, incorrect responses, slips, or other invalid performances occurred.

The experimental procedures were completed within a short testing window following supplementation to correspond with the expected onset of caffeine's acute physiological effects. The fixed testing sequence was maintained across both experimental conditions to ensure consistency between visits.

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Faculty of Physical Education and Sport, Comenius University in Bratislava (Approval Number 15/2024). All participants provided written informed consent before participation.

03

Conditions studied

  • Healthy Adult Male

Browse trials for

Keywords

  • Caffeine
  • Athletes
  • Exercise
  • Muscle Strength
  • Psychomotor Performance
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active male amateur soccer players competing in Slovakian 3rd to 6th tier-league and Austrian 4th to 7th tier-league,
  • Regular participation in soccer training and competition,
  • No current health restrictions preventing participation in maximal physical testing
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Goalkeepers
  • Current or recent musculoskeletal injury affecting physical performance
  • Acute illness at the time of testing
  • Cardiovascular or neurological disorders
  • Visual impairment affecting performance of the experimental tasks
  • Significant sleep disorders
  • Habitual caffeine consumption exceeding 400 mg/day
  • Failure to complete both experimental sessions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Caffeine ingestion

    Supplementation was administered as caffeine capsules (Scitec Nutrition Caffeine, 100 milligrams per capsule). Participants received 300 mg of caffeine, which represented approximately 3.74 milligrams/kilograms of mean body mass. This dosage corresponded to an individual dose ranging from 3.16 to 4.44 milligrams/kilograms of mean of body mass. The capsules were visually identical, and neither the testers nor the participants were aware of the assigned condition. Caffeine was ingested 30 minutes before the testing session.

    Dietary Supplement: Caffeine 300 MG

  • Placebo comparator
    Placebo ingestion

    Supplementation was administered as a placebo capsules filled with potato starch. The capsules were visually identical, and neither the testers nor the participants were aware of the assigned condition. Placebo pills were ingested 30 minutes before the testing session.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementCaffeineStudies of CaffeineCaffeine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Supplementation was administered as caffeine capsules (Scitec Nutrition Caffeine, 100 milligrams per capsule). Subjects received 300 milligrams of caffeine, which represented an individual dose ranging from 3.16 to 4.44 milligrams/kilograms of body mass.

    Also known as: caffeine pills

  • Dietary supplementPlacebo

    Supplementation was administered as placebo capsules filled with potato starch. The capsules were visually identical, and neither the testers nor the participants were aware of the assigned condition.

06

What researchers measure

Primary outcomes

  1. Planned Agility

    The running course was divided into two sections. The first section consisted of a 5 meter linear sprint from a two-point starting position. At the end of the linear section, two cones positioned 1-meter apart marked the change-of-direction area. The participant was instructed by the tester to change the direction of sprinting by cutting at a 45° angle to either the left or right side. The primary outcome measure was the fastest trial completion time, recorded in seconds using a photocell timing system. Timing commenced when the participant crossed the starting gate and ended when the participant crossed the designated gate at the end of course.

    Time frame: 40 minutes after caffeine/placebo ingestion

  2. Reactive Agility

    The running course was divided into two sections. The first section consisted of a 5 meter linear sprint from a two-point starting position. At the end of the linear section, two cones positioned 1-meter apart marked the change-of-direction area. The participant was instructed by the tester to change the direction of sprinting according to the a) light sensor, b) human movement, by cutting at a 45° angle to either the left or right side. 1. Light sensor showed green arrow of dedicated change-of-direction. This stimulus occured 500 milliseconds after crossing the starting gate. 2. Human tester executed movement to the side when participants were 2.5 meters apart from starting gate. Participants were reacting by the execution of change-of-direction to the opposite side as human tester. The outcome was the fastest completion time, recorded in seconds using a photocell timing system.

    Time frame: 45 minutes after caffeine/placebo ingestion

Secondary outcomes

  1. Countermovement jump

    Assessment of vertical power production by the lower limbs, evaluated as maximum countermovement jump height in centimeters.

    Time frame: 30 minutes after caffeine/placebo ingestion

  2. Drop jump 30

    Assessment of reactive strength of the lower limbs, evaluated as the maximum reactive strength index (RSI) calculated from flight time and contact time during a drop jump from a 30 centimeter box.

    Time frame: 35 minutes after caffeine/placebo ingestion

07

Study locations

1 site
  • Comenius University in Bratislava, Faculty of Physical Education and Sport
    Bratislava, Slovakia 814 69, Slovakia
08

References and documents

Publications

  • Redondo B, Jimenez R, Molina R, Dalton K, Vera J. Effects of caffeine ingestion on dynamic visual acuity: a placebo-controlled, double-blind, balanced-crossover study in low caffeine consumers. Psychopharmacology (Berl). 2021 Dec;238(12):3391-3398. doi: 10.1007/s00213-021-05953-1. Epub 2021 Aug 22. PubMed 34420061 ↗
  • Grgic J. Exploring the minimum ergogenic dose of caffeine on resistance exercise performance: A meta-analytic approach. Nutrition. 2022 May;97:111604. doi: 10.1016/j.nut.2022.111604. Epub 2022 Jan 22. PubMed 35203046 ↗
  • Merino Fernandez M, Ruiz-Moreno C, Giraldez-Costas V, Gonzalez-Millan C, Matos-Duarte M, Gutierrez-Hellin J, Gonzalez-Garcia J. Caffeine Doses of 3 mg/kg Increase Unilateral and Bilateral Vertical Jump Outcomes in Elite Traditional Jiu-Jitsu Athletes. Nutrients. 2021 May 18;13(5):1705. doi: 10.3390/nu13051705. PubMed 34069892 ↗
  • Ellis M, Noon M, Myers T, Clarke N. Low Doses of Caffeine: Enhancement of Physical Performance in Elite Adolescent Male Soccer Players. Int J Sports Physiol Perform. 2019 May 1;14(5):569-575. doi: 10.1123/ijspp.2018-0536. Epub 2019 Apr 21. PubMed 30300047 ↗
  • Stojanovic E, Scanlan AT, Milanovic Z, Fox JL, Stankovic R, Dalbo VJ. Acute caffeine supplementation improves jumping, sprinting, and change-of-direction performance in basketball players when ingested in the morning but not evening. Eur J Sport Sci. 2022 Mar;22(3):360-370. doi: 10.1080/17461391.2021.1874059. Epub 2021 Feb 2. PubMed 33413049 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Oct 2024, 0 months.

Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's 0 months is below that.

Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 28, 2026
StartActual
Oct 21, 2024
Primary completionActual
Oct 28, 2024
CompletionActual
Dec 20, 2024
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844122
Lead sponsor
Comenius University
Responsible party
Filip Skala (Research Assistant, Comenius University) — Principal investigator
First posted
Sep 28, 2026
Start date
Oct 21, 2024
Primary completion
Oct 28, 2024
Completion
Dec 20, 2024
Last update
Sep 28, 2026

Study contacts

Filip Skala, PhD.
principal investigator · Comenius University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Caffeine

Start the discussion